King's College London

Research portal

Antiparkinsonian effects of a metabotropic glutamate receptor 4 agonist in MPTP-treated marmosets

Research output: Contribution to journalArticlepeer-review

Standard

Antiparkinsonian effects of a metabotropic glutamate receptor 4 agonist in MPTP-treated marmosets. / Mann, Lizzie; Jackson, Michael; Lincoln, Louise et al.

In: Journal of parkinsons disease, 28.07.2020.

Research output: Contribution to journalArticlepeer-review

Harvard

Mann, L, Jackson, M, Lincoln, L, Fisher, R, Rose, S & Duty, S 2020, 'Antiparkinsonian effects of a metabotropic glutamate receptor 4 agonist in MPTP-treated marmosets', Journal of parkinsons disease.

APA

Mann, L., Jackson, M., Lincoln, L., Fisher, R., Rose, S., & Duty, S. (2020). Antiparkinsonian effects of a metabotropic glutamate receptor 4 agonist in MPTP-treated marmosets. Journal of parkinsons disease.

Vancouver

Mann L, Jackson M, Lincoln L, Fisher R, Rose S, Duty S. Antiparkinsonian effects of a metabotropic glutamate receptor 4 agonist in MPTP-treated marmosets. Journal of parkinsons disease. 2020 Jul 28.

Author

Mann, Lizzie ; Jackson, Michael ; Lincoln, Louise et al. / Antiparkinsonian effects of a metabotropic glutamate receptor 4 agonist in MPTP-treated marmosets. In: Journal of parkinsons disease. 2020.

Bibtex Download

@article{1c5347e6d91c4a0d9614b107efdcf130,
title = "Antiparkinsonian effects of a metabotropic glutamate receptor 4 agonist in MPTP-treated marmosets",
abstract = "Background: Increased firing across glutamatergic synapses may contribute to both the motor dysfunction and L-DOPA-induced dyskinesia seen in Parkinson{\textquoteright}s disease. Given their ability to reduce glutamate release, activation of group III metabotropic glutamate receptors such as metabotropic glutamate receptor 4 may prove effective against both motor dysfunction and dyskinesia in Parkinson{\textquoteright}s disease. Objectives: We hypothesised that activation of metabotropic glutamate receptor 4 by an orthosteric agonist ((2S)-2-amino-4-(hydroxy(hydroxy(4-hydroxy-3-methoxy-nitrophenyl)methyl)phosphoryl)butanoic acid, LSP1-2111) would produce antiparkinsonian activity and reduce expression of dyskinesia in a 1-methyl-4-phenyl,1,2,3,6-tetrahydropyridine (MPTP)-treated marmoset model of Parkinson{\textquoteright}s disease.Methods: Common marmosets were previously treated with MPTP and pre-primed with L-DOPA for up to 28 days to express dyskinesia. LSP1-2111 (1, 3 or 6 mg/kg s.c.) or vehicle (0.9% saline s.c.) were administered immediately prior to L-DOPA (8 mg/kg + benserazide (10 mg/kg) p.o.) or vehicle (10% sucrose p.o.). Locomotor activity was measured in automated test cages and animals were scored for dyskinesia and disability.Results: As expected, L-DOPA reversed motor disability and induced moderate dyskinesia. By contrast, LSP1-2111 alone significantly reduced the motor disability without any accompanying expression of dyskinesia. When administered in combination with L-DOPA, LSP1-2111 did not significantly reduce the severity of L-DOPA-induced dyskinesia.Conclusions: Systemic administration of LSP1-2111 reduces motor disability without causing dyskinesia in MPTP-treated marmosets, supporting a role for metabotropic glutamate receptor 4 orthosteric agonists as promising monotherapy for PD. Conversely, this study found no evidence to support their use as antidyskinetic agents within the dose range tested. ",
author = "Lizzie Mann and Michael Jackson and Louise Lincoln and Ria Fisher and Sarah Rose and Susan Duty",
note = "This work was funded by an MRC PhD CASE Studentship joint with Eisai Ltd., awarded to EM under the supervision of Dr Peter Atkinson.",
year = "2020",
month = jul,
day = "28",
language = "English",
journal = "Journal of parkinsons disease",
issn = "1877-7171",
publisher = "IOS Press",

}

RIS (suitable for import to EndNote) Download

TY - JOUR

T1 - Antiparkinsonian effects of a metabotropic glutamate receptor 4 agonist in MPTP-treated marmosets

AU - Mann, Lizzie

AU - Jackson, Michael

AU - Lincoln, Louise

AU - Fisher, Ria

AU - Rose, Sarah

AU - Duty, Susan

N1 - This work was funded by an MRC PhD CASE Studentship joint with Eisai Ltd., awarded to EM under the supervision of Dr Peter Atkinson.

PY - 2020/7/28

Y1 - 2020/7/28

N2 - Background: Increased firing across glutamatergic synapses may contribute to both the motor dysfunction and L-DOPA-induced dyskinesia seen in Parkinson’s disease. Given their ability to reduce glutamate release, activation of group III metabotropic glutamate receptors such as metabotropic glutamate receptor 4 may prove effective against both motor dysfunction and dyskinesia in Parkinson’s disease. Objectives: We hypothesised that activation of metabotropic glutamate receptor 4 by an orthosteric agonist ((2S)-2-amino-4-(hydroxy(hydroxy(4-hydroxy-3-methoxy-nitrophenyl)methyl)phosphoryl)butanoic acid, LSP1-2111) would produce antiparkinsonian activity and reduce expression of dyskinesia in a 1-methyl-4-phenyl,1,2,3,6-tetrahydropyridine (MPTP)-treated marmoset model of Parkinson’s disease.Methods: Common marmosets were previously treated with MPTP and pre-primed with L-DOPA for up to 28 days to express dyskinesia. LSP1-2111 (1, 3 or 6 mg/kg s.c.) or vehicle (0.9% saline s.c.) were administered immediately prior to L-DOPA (8 mg/kg + benserazide (10 mg/kg) p.o.) or vehicle (10% sucrose p.o.). Locomotor activity was measured in automated test cages and animals were scored for dyskinesia and disability.Results: As expected, L-DOPA reversed motor disability and induced moderate dyskinesia. By contrast, LSP1-2111 alone significantly reduced the motor disability without any accompanying expression of dyskinesia. When administered in combination with L-DOPA, LSP1-2111 did not significantly reduce the severity of L-DOPA-induced dyskinesia.Conclusions: Systemic administration of LSP1-2111 reduces motor disability without causing dyskinesia in MPTP-treated marmosets, supporting a role for metabotropic glutamate receptor 4 orthosteric agonists as promising monotherapy for PD. Conversely, this study found no evidence to support their use as antidyskinetic agents within the dose range tested.

AB - Background: Increased firing across glutamatergic synapses may contribute to both the motor dysfunction and L-DOPA-induced dyskinesia seen in Parkinson’s disease. Given their ability to reduce glutamate release, activation of group III metabotropic glutamate receptors such as metabotropic glutamate receptor 4 may prove effective against both motor dysfunction and dyskinesia in Parkinson’s disease. Objectives: We hypothesised that activation of metabotropic glutamate receptor 4 by an orthosteric agonist ((2S)-2-amino-4-(hydroxy(hydroxy(4-hydroxy-3-methoxy-nitrophenyl)methyl)phosphoryl)butanoic acid, LSP1-2111) would produce antiparkinsonian activity and reduce expression of dyskinesia in a 1-methyl-4-phenyl,1,2,3,6-tetrahydropyridine (MPTP)-treated marmoset model of Parkinson’s disease.Methods: Common marmosets were previously treated with MPTP and pre-primed with L-DOPA for up to 28 days to express dyskinesia. LSP1-2111 (1, 3 or 6 mg/kg s.c.) or vehicle (0.9% saline s.c.) were administered immediately prior to L-DOPA (8 mg/kg + benserazide (10 mg/kg) p.o.) or vehicle (10% sucrose p.o.). Locomotor activity was measured in automated test cages and animals were scored for dyskinesia and disability.Results: As expected, L-DOPA reversed motor disability and induced moderate dyskinesia. By contrast, LSP1-2111 alone significantly reduced the motor disability without any accompanying expression of dyskinesia. When administered in combination with L-DOPA, LSP1-2111 did not significantly reduce the severity of L-DOPA-induced dyskinesia.Conclusions: Systemic administration of LSP1-2111 reduces motor disability without causing dyskinesia in MPTP-treated marmosets, supporting a role for metabotropic glutamate receptor 4 orthosteric agonists as promising monotherapy for PD. Conversely, this study found no evidence to support their use as antidyskinetic agents within the dose range tested.

M3 - Article

JO - Journal of parkinsons disease

JF - Journal of parkinsons disease

SN - 1877-7171

ER -

View graph of relations

© 2020 King's College London | Strand | London WC2R 2LS | England | United Kingdom | Tel +44 (0)20 7836 5454